GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bide Pharmatech Co Ltd (SHSE:688073) » Definitions » EBIT

Bide Pharmatech Co (SHSE:688073) EBIT : ¥102 Mil (TTM As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Bide Pharmatech Co EBIT?

Bide Pharmatech Co's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was ¥39 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was ¥102 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Bide Pharmatech Co's annualized ROC % for the quarter that ended in Sep. 2024 was 19.09%. Bide Pharmatech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 18.73%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Bide Pharmatech Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 2.94%.


Bide Pharmatech Co EBIT Historical Data

The historical data trend for Bide Pharmatech Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bide Pharmatech Co EBIT Chart

Bide Pharmatech Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial 7.45 72.15 115.48 173.94 128.53

Bide Pharmatech Co Quarterly Data
Dec18 Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.06 -5.00 32.17 35.49 38.97

Competitive Comparison of Bide Pharmatech Co's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Bide Pharmatech Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bide Pharmatech Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bide Pharmatech Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bide Pharmatech Co's EV-to-EBIT falls into.


;
;

Bide Pharmatech Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥102 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bide Pharmatech Co  (SHSE:688073) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Bide Pharmatech Co's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=209.248 * ( 1 - 16.06% )/( (875.536 + 964.213)/ 2 )
=175.6427712/919.8745
=19.09 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2314.147 - 216.087 - ( 1222.524 - max(0, 296.015 - 2177.019+1222.524))
=875.536

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2352.165 - 216.104 - ( 1171.848 - max(0, 316.007 - 2160.697+1171.848))
=964.213

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Bide Pharmatech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=155.86/( ( (88.148 + max(701.413, 0)) + (147.246 + max(727.161, 0)) )/ 2 )
=155.86/( ( 789.561 + 874.407 )/ 2 )
=155.86/831.984
=18.73 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(231.257 + 686.132 + 26.289) - (216.087 + 0 + 26.178)
=701.413

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(229.31 + 709.916 + 31.585) - (216.104 + 0 + 27.546)
=727.161

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Bide Pharmatech Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=101.627/3451.130
=2.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bide Pharmatech Co EBIT Related Terms

Thank you for viewing the detailed overview of Bide Pharmatech Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Bide Pharmatech Co Business Description

Traded in Other Exchanges
N/A
Address
No. 128, Xiangyin Road, Room 101, Block A, Building 11, Yangpu District, Shanghai, CHN, 200433
Bide Pharmatech Co Ltd is engaged in the research and development, design, production and sales of drug molecular building blocks.
Executives
Dai Lan Director

Bide Pharmatech Co Headlines

No Headlines